Reading 'corporation grief' as 'corporate greed' - To play devil's advocate here for a moment, the drug development and approval processes are crazy expensive,

Reading 'corporation grief' as 'corporate greed' - To play devil's advocate here for a moment, the drug development and approval processes are crazy expensive, and the pharmacos basically charge what the market will bear for each product, and spread the revenue to all costs - not necessarily allocated by individual drugs. IOW, drug A costs a little and sells for a lot, drug B the reverse, but the total revenue covers the cost and some profit. At least that's the argument the pharmacos make in public. If this situation is not as it should be, someone should articulate what's wrong and how to fix it. E.g. patients can't afford something they're dying without, but if the vendors are forced to discount for some drugs or some buyers, how is the whole business to be financed? I can think of arguments for and against various possible reforms, but won't bore you here. We do need something more specific tho.